Table 2.

Concomitant medication with potential impact on the cardiovascular system

	Vericiguat + nitroglycerin (n = 24)	Placebo + nitroglycerin (n = 12)
Number of patients (%) with at least one concomitant medication	24 (100.0)	12 (100.0)
Blood and blood‐forming organs	24 (100.0)	12 (100.0)
Platelet aggregation inhibitors	24 (100.0)	11 (91.7)
Cardiovascular system	24 (100.0)	12 (100.0)
ACE inhibitors	15 (62.5)	9 (75.0)
Aldosterone receptor antagonists (MRAs)	3 (12.5)	0 (0.0)
α‐blocking and β‐blocking agents	1 (4.2)	1 (8.3)
β‐blockers	19 (79.2)	9 (75.0)
Angiotensin II antagonists	5 (20.8)	2 (16.7)
Angiotensin II antagonists and diuretics	4 (16.7)	0 (0.0)
Antiarrhythmics, Class IB	1 (4.2)	0 (0.0)
Dihydropyridine derivatives	4 (16.7)	2 (16.7)
Heparins or heparinoids for topical use	1 (4.2)	0 (0.0)
HMG‐CoA reductase inhibitors	22 (91.7)	12 (100.0)
Hydrazinophthalazine derivatives	2 (8.3)	0 (0.0)
Other cardiac preparations a	4 (16.7)	3 (25.0)
Other lipid‐modifying agents	2 (8.3)	0 (0.0)
Other potassium‐sparing agents	0 (0.0)	1 (8.3)
Products containing corticosteroids	1 (4.2)	0 (0.0)
Products containing local anesthetics	1 (4.2)	0 (0.0)
Sulfonamides	3 (12.5)	1 (8.3)
Thiazides	0 (0.0)	1 (8.3)

ACE, angiotensin‐converting enzyme; HMG‐CoA, 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A; MRA, mineralocorticoid receptor antagonist.

^a Ibuprofen or ivabradine hydrochloride.